[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353900-105":59,"doc-detail-353900-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","challenging-and-successful-therapy-decision-making-for-aml-post-cytotoxic-therapy-and-concomitant-active-breast-cancer-a-case-report-and-experience-driven-strategy","Challenging and Successful Therapy Decision-Making for AML Post Cytotoxic Therapy and Concomitant Active Breast Cancer - A Case Report and Experience-Driven Strategy","","Breast cancer survivors may develop acute myeloid leukemia following prior cytotoxic therapy, creating a high-stakes need for coordinated treatment decisions when a second, active breast malignancy is present. A 48-year-old woman experienced AML after earlier breast-conserving treatment and later developed active contralateral disease alongside hematologic abnormalities. After multidisciplinary planning, left breast conserving surgery was performed, followed by intensive induction (“3+7”) and consolidation chemotherapy achieving complete leukemia remission with negative measurable residual disease, then allogeneic hematopoietic cell transplantation. Three years post-transplant, she remains in complete remission across all three neoplasms.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/challenging-and-successful-therapy-decision-making-for-aml-post-cytotoxic-therapy-and-concomitant-active-breast-cancer-a-case-report-and-experience-driven-strategy/353900/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/challenging-and-successful-therapy-decision-making-for-aml-post-cytotoxic-therapy-and-concomitant-active-breast-cancer-a-case-report-and-experience-driven-strategy/353900.png","ImageObject",300,407,{"name":92,"@type":93},"Jake","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What complication connects breast cancer treatment and AML-pCT in this report?","Question",{"text":112,"@type":113},"The report focuses on acute myeloid leukemia post cytotoxic therapy (AML-pCT) occurring after prior breast cancer therapies, including radiotherapy and chemotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the patient diagnosed when symptoms appeared before left breast surgery?",{"text":117,"@type":113},"Before the second breast surgery, leukocytosis, anemia, and thrombocytopenia prompted hematological evaluation, which confirmed AML-pCT.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment strategy led to remission and what was the outcome after transplantation?",{"text":121,"@type":113},"After multidisciplinary planning, the patient underwent left breast conserving surgery, intensive “3+7” induction and consolidation chemotherapy to achieve complete remission with negative measurable residual disease, and then allogeneic hematopoietic cell transplantation. Three years later, she remains in complete remission for all three neoplasms.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353900,1790504165,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Breast Cancer: Targets and Therapy  \nOpen Access Full Text Article C ASE REPORT  \nChallenging and Successful Therapy DecisionMaking for AML Post Cytotoxic Therapy and Concomitant Active Breast Cancer – A Case Report and Experience-Driven Strategy  \nMateusz Wichtowski 1 , Monika Adamska 2 , Anna Łojko-Dankowska 2 , Lidia Gil 2  \n1Department of Surgical Oncology, Institute of Oncology; Poznan University of Medical Sciences, Poznan, Poland; 2Department of Hematology, Transplantation and Cellular Therapies; Poznan University of Medical Sciences, Poznan, Poland  \nCorrespondence: Monika Adamska, Department of Hematology, Transplantation and Cellular Therapies; Poznan University of Medical Sciences, Szamarzewskiego 84 St, Poznań, 60-569, Poland, [Email mmadamskaa@gmail.com](Email mmadamskaa@gmail.com)  \n\n| Background: Breast cancer (BC) represents the most frequent female malignancy worldwide, and one of the rare, however lifethreatening, complications after oncological treatment is acute myeloid leukemia post cytotoxic therapy (AML-pCT) . Moreover, most AML-pCT cases have contributed to previous BC cytotoxic therapies. The treatment approach for AML-pCT in BC survivors with an active second BC represents the challenging decision-making process that is described in this report.\u003Cbr>Results: A 48-year-old woman was diagnosed with invasive lobular carcinoma of the right breast (T2N0M0, BRCA1 negative) and successfully treated with breast-conserving therapy, adjuvant radiotherapy, and hormone therapy. Seven years later, she was diagnosed with ductal carcinoma in situ in the left breast, and unexpectedly, directly before the surgery, with leukocytosis, anemia, and thrombocytopenia. Hematological investigation revealed a diagnosis of AML-pCT (intermediate ELN2022 risk group) . After a management conference involving both oncologists and haematologists, conserving surgery of the left breast (pTis, pNX) was performed. Seven days later the patient started intensive antileukemic treatment with “3+7” induction chemotherapy, followed by two consolidation chemotherapies, which resulted in complete remission (CR) of leukemia with negative measurable residual disease. Despite a high hematopoietic cell transplantation comorbidity index score (due to a previous neoplasm), the patient qualified forallogeneic hematopoietic cell transplantation (alloHCT) . The procedure was performed using myeloablative conditioning with a matched unrelated donor. Currently, 3 years post-alloHCT, the patient remains in CR for all three neoplasms.\u003Cbr>Conclusion: In this case report, we describe the therapeutic success of intensive alloHCT in AML-pCT patient with active BC. The presented treatment approach for active BC and AML-pCT requires collaboration between oncologists and hematologists to ensure fast decision-making.\u003Cbr>Keywords: breast cancer, acute myeloid leukemia post cytotoxic therapy, case report |\n| --- |\n| Introduction\u003Cbr>Breast cancer (BC) represents the most frequent female malignancy worldwide, with the highest oncological mortality.1 Approximately one in eight woman will develop BC in the duration of her life.2 One of the rare, however lifethreatening, unintended complications of BC treatment is acute myeloid leukemia post cytotoxic therapy (AML-pCT), which can occur after the use of successful primary cancer radiotherapy, chemotherapy or poly-ADP-ribose polymerase1 (PARP1) inhibitors.3,4\u003Cbr>AML-pCT constitutes 20% of all acute myeloid leukemias and represents a subtype with a poor prognosis, with an estimated overall survival of 7–10 months and a complete response rate of 30% .5–7 The disease is characterized by adverse genetic abnormalities and a complex karyotype. Genes involved in the pathogenesis of AML-pCT can be grouped into functional classes: epigenetic regulators (ASXL1, DNMT3A, EZH2, IDH1/IDH2, TET2), transcription |\n\n[https://doi.org/10.2147/BCTT.S536327](https://doi.org/10.2147/BCTT.S536327)  \n[Received: 15 May 2025](Received: 15 May 2025)  ","cbCaieiQ1JALbCK6","https://ap.wps.com/l/cbCaieiQ1JALbCK6","pdf",455892,"English","# Background\n# Results\n# Conclusion\n# Introduction\n# Case Report","[{\"question\":\"What complication connects breast cancer treatment and AML-pCT in this report?\",\"answer\":\"The report focuses on acute myeloid leukemia post cytotoxic therapy (AML-pCT) occurring after prior breast cancer therapies, including radiotherapy and chemotherapy.\"},{\"question\":\"How was the patient diagnosed when symptoms appeared before left breast surgery?\",\"answer\":\"Before the second breast surgery, leukocytosis, anemia, and thrombocytopenia prompted hematological evaluation, which confirmed AML-pCT.\"},{\"question\":\"What treatment strategy led to remission and what was the outcome after transplantation?\",\"answer\":\"After multidisciplinary planning, the patient underwent left breast conserving surgery, intensive “3+7” induction and consolidation chemotherapy to achieve complete remission with negative measurable residual disease, and then allogeneic hematopoietic cell transplantation. Three years later, she remains in complete remission for all three neoplasms.\"}]","Challenging and Successful Therapy Decision-Making for AML Post Cytotoxic Therapy and Concomitant Active Breast Cancer - A Case Report and Experience-Driven Strategy | PDF",1790107818,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df1b77ab4f6b47c02be5d69895b673fc.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22b3a0f9d4d20e04e6a6ed42bad79ce2.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f9172fbfe386e1c0f810b6d0dcc0d9e.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d2e67a81585e9bac712e60e64ad1ce1.webp",980,756]